FY2024 Earnings Estimate for Certara Issued By William Blair

Certara, Inc. (NASDAQ:CERT - Free Report) - Analysts at William Blair increased their FY2024 earnings per share (EPS) estimates for Certara in a report released on Wednesday, January 15th. William Blair analyst M. Smock now forecasts that the company will earn $0.28 per share for the year, up from their prior forecast of $0.27. The consensus estimate for Certara's current full-year earnings is $0.28 per share.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business's revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.06 EPS.

Several other equities analysts also recently weighed in on the company. Robert W. Baird dropped their price objective on Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a research note on Tuesday, November 5th. Barclays reduced their target price on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, November 7th. Finally, UBS Group raised Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target for the company in a research report on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $15.92.

Certara Price Performance

Shares of CERT stock traded down $0.10 during midday trading on Friday, reaching $11.66. 912,516 shares of the company traded hands, compared to its average volume of 989,011. The firm's 50 day simple moving average is $10.90 and its two-hundred day simple moving average is $11.95. The firm has a market cap of $1.88 billion, a PE ratio of -58.30, a price-to-earnings-growth ratio of 4.55 and a beta of 1.52. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara has a 1-year low of $9.41 and a 1-year high of $19.87.

Hedge Funds Weigh In On Certara

A number of large investors have recently modified their holdings of CERT. The Manufacturers Life Insurance Company increased its position in Certara by 4.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company's stock worth $317,000 after purchasing an additional 975 shares in the last quarter. Nicolet Advisory Services LLC increased its holdings in Certara by 6.6% during the 3rd quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company's stock worth $273,000 after purchasing an additional 1,531 shares during the last quarter. KBC Group NV raised its position in shares of Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock valued at $57,000 after purchasing an additional 1,584 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Certara by 112.3% during the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company's stock valued at $46,000 after buying an additional 2,076 shares during the last quarter. Finally, Everence Capital Management Inc. grew its position in shares of Certara by 21.0% during the third quarter. Everence Capital Management Inc. now owns 14,910 shares of the company's stock worth $175,000 after buying an additional 2,590 shares in the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.